LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS)
$0.0016 0 (0%)
Analysed LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS) News Sources
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
14-04-2026
yahoo.com
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
06-04-2026
fool.com
Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year
04-04-2026
yahoo.com
CLO Sells LGND 5,000 Shares for $1.0 Million
31-03-2026
fool.com
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know
27-03-2026
fool.com
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
26-03-2026
yahoo.com
Two Biotech Stocks Hover Near Highs; Natural Gas And Finance Names Show Resilience
20-03-2026
yahoo.com
Oracle, Nike upgraded: Wall Street's top analyst calls
11-03-2026
yahoo.com
Rice Hall James Loads Up on BIRK With 466,000 Shares Bought
09-03-2026
fool.com
Rice Hall James Buys QuidelOrtho Stock
09-03-2026
fool.com
What is the current price of LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS)?
The current price of LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS) is $0.0016.
LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS) absolute price change since previous trading day?
The absolute price change of LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS) since the previous trading day is $0.
LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS) percentage price change since previous trading day?
The percentage price change of LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS) since the previous trading day is 0%.
What is the most recent average sentiment score for LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS)?
The most recent average sentiment score for LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS) is 78 out of 100.
What is the most recent average sentiment for LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS)?
The most recent sentiment for LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS) is .
SEC-8K** Filing Available For LIGAND PHARMA-ROCHE CVR (LGNDZ:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.